The Phase III DIAMOND trial met both its primary and secondary endpoints of reducing tics in both children and adult patients ...
Emalex Biosciences’ dopamine blocker led to fewer patients with Tourette syndrome relapsing in a phase 3 trial, setting the ...
In the Phase III trial, 41.9% of pediatric Tourette syndrome patients relapsed after ecopipam treatment, as compared with ...
Ecopipam showed statistical significance in treating Tourette syndrome versus a placebo for both its primary efficacy ...
Results from a Phase III registrational study suggest that ecopipam has potential as a first-in-class dopamine-1 receptor ...
Chicago, USA-based Emalex Biosciences announced positive top-line data from its Phase III registrational study of ecopipam, a ...
Emalex Biosciences met primary and secondary endpoints in its Phase 3 registrational trial of ecopipam for patients with ...
Emalex Biosciences said its daily oral tablet helped reduce relapses for children and adults with Tourette syndrome in a ...
“These results strengthen our confidence in ecopipam as a potential first-in-class treatment for patients with Tourette syndrome,” said Frederick Munschauer, MD, Emalex Biosciences chief ...
Emalex Biosciences announced positive topline data from its Phase 3 registrational study of ecopipam, a novel dopamine-1 receptor antagonist, in subjects with Tourette syndrome.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback